What is ZOE?
ZOE operates at the intersection of health science and advanced technology, leveraging artificial intelligence and mobile digital platforms to conduct large-scale research. By focusing on critical areas such as dietary inflammation, nutrition, and public health crises like COVID-19, the company provides actionable insights that bridge the gap between complex biological data and consumer health outcomes. Its market position is defined by its ability to transform raw scientific data into personalized health recommendations, effectively disrupting traditional nutritional science models through scalable, tech-enabled solutions.
How much funding has ZOE raised?
ZOE has raised a total of $63.2M across 3 funding rounds:
Series A
$10M
Series B
$50.7M
Other Financing Round
$2.5M
Series A (2021): $10M with participation from ThirdStream Partners and Softbank
Series B (2022): $50.7M led by Daphni, Accomplice, Ahren Innovation Capital, and L Catterton
Other Financing Round (2023): $2.5M supported by Steven Bartlett’s Flight Fund
Key Investors in ZOE
Daphni
Daphni is a venture capital firm that manages a portfolio of diverse startup companies across various sectors, including artificial intelligence, energy storage, healthcare, and sustainability.
Accomplice
Accomplice is a venture capital firm that invests in technology startup companies and is based in Massachusetts, United States.
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science.
What's next for ZOE?
Looking ahead, ZOE is poised to leverage its recent capital infusion to scale its research infrastructure and expand its digital health offerings. The strategic focus will likely center on deepening its AI capabilities to refine personalized nutrition algorithms and broadening its reach within the global wellness market. By maintaining a rigorous scientific standard while scaling its consumer-facing platform, ZOE is well-positioned to capitalize on the growing demand for evidence-based health technology. The company's trajectory suggests a transition toward broader clinical integration and potential expansion into new therapeutic domains, supported by its diverse base of institutional backers.
See full ZOE company page
